Rituximab for idiopathic membranous nephropathy
Rituximab for idiopathic membranous nephropathy
复制标题
DOI：
10.1016/s0140-6736(02)11042-7
复制
发表时间：
2002-09-21
期刊：
影响因子：
168.9
通讯作者：
Ruggenenti, P
中科院分区：
文献类型：
--
作者：
Remuzzi, G;Chiurchiu, C;Ruggenenti, P
特发性膜性肾病是肾病综合征的常见病因，其治疗方法毒性很大。考虑到B细胞在该病中的致病潜力，我们研究了8名患有持续性肾病综合征的特发性膜性肾病的患者每周4次输注利妥昔单抗（375 mg/m2）-B细胞抗原CD 20的单克隆抗体-的效果。在第4周和第20周，尿蛋白从平均（SE）8.6 g/24 h（1.4）分别下降至3.8（0.8）和3.7（0.9）（p
Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m(2))- the monoclonal antibody to B-cell antigen CD20-in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p